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Maturation of human immunodeficiency virus (HIV) depends on the processing of Gag and Pol polyproteins
by the viral protease, making this enzyme a prime target for anti-HIV therapy. Among the protease substrates,
the nucleocapsid-p1 (NC-p1) sequence is the least homologous, and its cleavage is the rate-determining step
in viral maturation. In the other substrates of HIV-1 protease, P1 is usually either a hydrophobic or an aro-
matic residue, and P2 is usually a branched residue. NC-p1, however, contains Asn at P1 and Ala at P2. In response
to the V82A drug-resistant protease mutation, the P2 alanine of NC-p1 mutates to valine (AP2V). To provide
a structural rationale for HIV-1 protease binding to the NC-p1 cleavage site, we solved the crystal structures
of inactive (D25N) WT and V82A HIV-1 proteases in complex with their respective WT and AP2V mutant
NC-p1 substrates. Overall, the WT NC-p1 peptide binds HIV-1 protease less optimally than the AP2V mutant,
as indicated by the presence of fewer hydrogen bonds and fewer van der Waals contacts. AlaP2 does not fill the
P2 pocket completely; PheP1 makes van der Waals interactions with Val82 that are lost with the V82A protease
mutation. This loss is compensated by the AP2V mutation, which reorients the peptide to a conformation more
similar to that observed in other substrate-protease complexes. Thus, the mutant substrate not only binds the
mutant protease more optimally but also reveals the interdependency between the P1 and P2 substrate sites.
This structural interdependency results from coevolution of the substrate with the viral protease.
Human immunodeficiency virus type 1 (HIV-1) matures af-
ter the viral protease processes (35) the Gag and Pol polypro-
teins at 10 substrate locations (3, 15). Therefore, inhibition of
HIV-1 protease represents an important avenue for antiviral
therapy (13, 48). The substrate sequences cleaved by the pro-
tease are nonhomologous (3), with the sequence of the nucleo-
capsid-p1 (NC-p1) substrate being the most different. In spite
of the poor sequence homology among the substrate sites, a
series of substrate-protease crystal structures led us to hypoth-
esize that substrate specificity in HIV-1 protease results from
the enzyme’s recognizing an asymmetric shape (or envelope)
rather than a particular amino acid sequence (40). This shape
results from the conformation that a particular substrate se-
quence can adopt, implying that an interdependency necessar-
ily exists among the different substrate residue sites.
All of the protease inhibitors whose designs were structure
based bind competitively (8, 18, 28, 52, 53) at the active site.
Since these inhibitors bind at the same site as the substrates,
many protease residues contact both substrates and inhibitors.
Drug resistance, which often develops in the presence of ther-
apeutic protease inhibitors, results from high viral turnover,
the infidelity of the viral reverse transcriptase (16, 42, 43), and
selective pressure on the virus. With drug resistance, the pro-
tease no longer binds as tightly to inhibitors but retains the
ability to recognize and cleave its substrate sites.
The first drug-resistant mutation that often occurs in pa-
tients, V82A (47), is frequently associated with indinavir or
ritonavir therapy (5, 9, 11, 30). Our previous studies have
shown that V82A is a prime site for drug resistance to occur, as
the valine at residue 82 is not critical for substrate recognition
but does extensively contact many of the commonly used in-
hibitors (39). However, the apparent coevolution of the NC-p1
cleavage site (AP2V) with the V82A mutation in the protease
(1, 10, 20, 55) implies that Val82 plays an important role in the
protease’s recognition of the NC-p1 substrate, a role that is lost
when the V82A mutation occurs.
Within the viral context, the NC-p1 cleavage site is the
slowest (50), final (37, 54), and, therefore, rate-determining
site in HIV-1 Gag to be processed by the viral protease (6, 37).
NC-p1 has a polar Asn at the P1 position, while a hydrophobic
or aromatic residue is found at the same location in the other
substrate sequences. An Ala occupies the P2 position of the
NC-p1 substrate, while a branched side chain (14) exists at P2
in the other substrate sequences. The rate and order in which
NC-p1 is cleaved may be dictated by its unusual sequence as
well as by the location of this site within the Gag polyprotein.
In several studies of drug-experienced patient viral se-
quences, the NC-p1 substrate cleavage site has been seen to
mutate (1, 6, 10, 24, 44, 55). The most frequently observed
change occurs at P2, where the alanine mutates to a valine in
viral sequences that also contain the V82A drug-resistant pro-
tease mutation. Selection for a valine at this site makes sense
as valine is the wild-type (WT) residue at P2 in another sub-
strate sequence, the capsid-p2 cleavage site. In fact, the WT
HIV-1 protease cleaves AP2V in the NC-p1 cleavage site more
efficiently than it cleaves the WT NC-p1 sequence (12).
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The present study focuses on elucidating the structural ra-
tionale for HIV-1 protease recognition of the NC-p1 cleavage
site. We determined the crystal structures of both the WT and
V82A HIV-1 proteases in complex with their respective NC-p1
substrates. As seen in our previous studies (40), there is an
interdependency between the substrate subsites throughout
the cleavage site sequence that allows for the sequence to be
recognized as a substrate sequence by HIV-1 protease.
MATERIALS AND METHODS
Nomenclature. HIV-1 protease variants (WT or V82A), the nucleocapsid-p1
(NC-p1) WT substrate, and its AP2V mutant substrate will be distinguished
throughout this article by subscript and superscript acronyms. For example,
WTNC-p1WT denotes the WT substrate NC-p1 in complex with the WT protease,
and AP2VNC-p1V82A denotes the AP2V mutant substrate in complex with the
V82A mutant protease.
Substrate peptides. Two decameric peptides, WTNC-p1 (P5 to P5: ERQAN*
FLGKI) and AP2VNC-p1 (P4 to P6: RQVN*FLGKIN), with sequences corre-
sponding to the NC-p1 substrate cleavage site within the Gag polyprotein, were
chosen as previously described (40). The slight difference in the regions of the
cleavage sites that were crystallized occurred because the AP2VNC-p1 peptide
(P5 to P5: ERQVN*FLGKI) was not very soluble, whereas the decameric
peptide (P4 to P6: RQVN*FLGKIN) was. Both peptides were purchased from
Quality Controlled Biochemicals Inc., Hopkinton, Mass.
Mutagenesis, protein purification, and crystallization. The protease was ex-
pressed from a synthetic gene optimized for Escherichia coli codon usage with
Q7K to prevent autoproteolysis (45). This gene was used as the starting template
for mutagenesis to introduce the D25N (to prevent the protease from cleaving its
substrates) and V82A substitutions. Mutations were made by using a Quick-
Change site-directed mutagenesis kit (Stratagene, La Jolla, Calif.).
Protein expression, isolation, and purification were carried out as previously
described (17). The purified protease, in 50% acetic acid, was then refolded by
rapid 10-fold dilution into a mixture of 0.05 M sodium acetate (pH 5.5), 10%
glycerol, 5% ethylene glycol, and 5 mM dithiothreitol (refolding buffer). The
diluted protein was concentrated on an Amicon ultrafiltration cell and dialyzed
to remove any residual acetic acid. Protease used for crystallization was further
purified by using a Pharmacia Superdex 75 fast-performance liquid chromatog-
raphy column equilibrated with refolding buffer.
Crystals were grown by the hanging drop, vapor diffusion method as previously
described (38, 39, 49). Stock solutions (25 mM) of substrate peptides used for
cocrystallization were dissolved in refolding buffer rather than in dimethyl sul-
foxide. The protein concentration was approximately 1 mg ml1. Small crystals
started appearing after 6 to 8 weeks, with the longest length between 0.1 and 0.2
mm.
Data collection. Crystals chosen for data collection were flash frozen in a
nitrogen stream. X-ray data on these cryocooled crystals were collected on our
in-house Rigaku X-ray generator with an R-axis IV image plate system. Approx-
imately 200 5-min frames were collected per crystal with 1-degree oscillations
and no overlap between frames. The frames were later integrated and scaled by
using the programs DENZO and ScalePack, respectively (29, 34). The WTNC-
p1WT and AP2VNC-p1V82A complexes diffracted up to 2.1 and 2.0 A˚, respectively.
Complete data collection statistics are listed in Table 1.
Structure solution and crystallographic refinement. The CCP4i interface to
the CCP4 suite and related software modules (4) was used for most of the op-
erations described in this section. The molecular replacement package AMoRe
(33) was used to solve the structures. X-ray data within 8.0 to 3.0 A˚ were used for
structure solution by employing a Patterson radius of 25 A˚. An inhibitor-protease
complex obtained from the Protein Data Bank (PDB code 1MTR) (27) was used
as the search model. The molecular replacement solutions had typical correlation
function and R values of 78 to 81 and 29 to 31%, respectively. After structure
solutions were obtained, Refmac5 (32) was used to perform a rigid body refine-
ment of 25 cycles on data to 3.0 A˚. Although the R values for both complexes
decreased slightly, the free R dropped considerably to just above 30%. ARP/
wARP (31) was used to improve the initial phases. Graphical rebuilding was
performed with CHAIN (46), and the substrate peptides were modeled. The real
space refinement package RSREF (2) was used to adjust the model to fit the
electron density maps. Repeated rounds of Refmac5 and manual rebuilding were
performed until the refinement converged. The final refinement statistics are also
listed in Table 1.
RESULTS
Overall structure of the complexes. Two decameric sub-
strate peptides corresponding to the Gag polyprotein cleav-
age sites of NC-p1 (ERQAN*FLGKI) and its AP2V mutant
(RQVN*FLGKIN) were crystallized in complex with inactive
(D25N) variants of WT and drug-resistant HIV-1 protease
having the V82A mutation (referred to as WTNC-p1WT and
AP2VNC-p1V82A complexes, respectively). Although the pep-
tides used for crystallization span a slightly different region of
the cleavage site (P5 to P5 and P4 to P6), these differences
are likely to have minimal or no effect on the bound confor-
mation of the substrate. From our previous experience with to
determine substrate complexes with HIV protease (38, 39, 49),
the P5 and P5 residues usually have no contact with the
protease and are often disordered in the electron density.
Thus, the presence or absence of P5 or P6 is unlikely to
impact how the substrate is packed in the active site. The
WTNC-p1WT and
AP2VNC-p1V82A complexes were refined to
respective resolutions of 2.1 and 2.0 A˚. Their crystallographic
statistics are listed in Table 1. Eight substrate residues (P4 to
P4) in the WTNC-p1WT complex and all 10 substrate residues
(P4 to P6) in the AP2VNC-p1V82A complex were identified
from the electron density maps. The side chains of GlnP3 in
both of these complexes are disordered. Otherwise, residues at
P2 to P3 were unambiguously located within the electron
density. The WTNC-p1WT complex has larger temperature
factors than the AP2VNC-p1V82A complex, with average over-
all temperature factors of 40 and 27 A˚2, respectively. The
higher temperature factors in the WTNC-p1WT complex could
be due to increased thermal motions, possibly resulting from a
more dynamic fit between the protein and substrate.
As observed in other HIV-1 protease-substrate complexes
(40, 51), the substrates exist in an extended -strand confor-
mation (Fig. 1). However, a difference between the two com-
plexes is observed in the  and  angles for the P1 and P1
residues that flank the scissile peptide bond (Fig. 1). The  and
 angles for the WTNC-p1WT complex are 60° and 34°, re-





Space group P212121 P212121
a (Å) 51.1 50.8
b (Å) 57.7 57.3
c (Å) 61.5 60.9
Z 4 4
Temperature (°C) 80 80
Resolution (Å) 2.1 2.0
Total number of reflections 38149 80252
Number of unique reflections 10450 12492
Rmerge (%) 9.2 7.5
Completeness (%) 94.1 99.7
I/I 4.5 9
Crystallographic refinement
R value (%) 20.6 19.5
Rfree (%) 23.3 23.1
Sigma cutoff 0 0
RMSDa in:
Bond lengths (Å) 0.004 0.005
Bond angles (°) 1.5 1.3
a RMSD, root mean square deviation.
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spectively, for P1 and 50° and 152°, respectively, for P1,
whereas for the AP2VNC-p1V82A complex, they are 72° and
87°, respectively, for P1 and 102° and 143°, respectively, for
P1. These angles are still in the “generally allowed -strand
region” of the Ramachandran plot (41). Significant shifts are
seen in the  angle of P1 (53o) and the  angle of P1 (52o),
resulting in a large change in the orientation of the P1 carbonyl
oxygen (Fig. 1).
Double difference plots were calculated (39) in order to
elucidate regions where changes have occurred between the
FIG. 1. Conformation of the NC-p1 substrates. Stereo diagram of the superposition of the WT (cyan) and AP2V (magenta) variants of NC-p1
peptides. An arrow indicates the difference in conformation of the scissile bonds between the two structures. The superposition was based on
structurally conserved parts of the respective protease structures. Disordered side chains, whose conformation could not be resolved in the electron
density, have their names listed in parentheses.
FIG. 2. Double difference plots. Relative shifts in the V82A complexes in reference to the corresponding WT complexes with NC-p1 (a), CA-p2
(b), and p1-p6 (c). Double difference plots contour differences in internal C-C distances between two complexes. Each contour line represents
a deviation by 0.25 A˚. Black, green, blue, and red distinguish the contour ranges 1.0 A˚ and below, 1.0 to 0.5 A˚, 0.5 to 1.0 A˚, and 1 A˚ and
above, respectively. In panel a, box A corresponds to conformational changes between the P1 loops (Gly78-Asn83) from each of the two monomers,
and boxes B1 and B2 correspond to the conformational changes between the P1 loop with respect to the flap (Ile50) within each of the two
monomers. All of the boxed regions emphasize internal regions of the protease whose relative conformation has changed by more than 1.0 A˚
between the two complexes.
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-carbon backbones of the WTNC-p1WT and
AP2VNC-p1V82A
complexes (Fig. 2a). Double difference plots allow for compar-
ison of two complexes without superimposing them and, thus,
are unbiased by which residues are chosen for the superposi-
tion. To compute these plots, the distances between all the C
atoms within each of the complexes are calculated, and the
difference in these C-C distances between the two com-
plexes is mapped as a contour plot. The contour plot indicates
that the P1 loops (Gly78-Asn83) in the two monomers are
more than 1A˚ farther apart in the WTNC-p1WT complex than
in the AP2VNC-p1V82A complex (Fig. 2a, box A). Similarly, the
distances between the P1 loops and the flaps within the mono-
mers are larger in the WTNC-p1WT complex (Fig. 2a, boxes B1
and B2). These two observations suggest that the P1 loops in
the AP2VNC-p1V82A complex have moved closer to each other
in response to amino acid modifications at position 82 and at
P2 in the substrate (Fig. 3a). Calculation of the shape comple-
mentarity (21) between the two substrates and their respective
proteases shows that the complementarity is much better for
the AP2VNC-p1V82A complex (0.71) than for the
WTNC-p1WT
complex (0.58). Thus, the AP2V substrate appears to fit more
tightly within the V82A HIV-1 protease than the WT substrate
within its protease.
We have previously determined the crystal structures of the
WT and V82A protease variants with three other Gag polypro-
tein substrates: MA-CA, CA-p2, and p1-p6 (39, 40). Based on
FIG. 3. Superposition of WT and V82A complexes. (a) Stereo diagram of the superimposed active site residues in the WTNC-p1WT (in gray and
cyan) and AP2VNC-p1V82A (in magenta and purple) complexes. Protease residues within 4.2A˚ of the substrate are shown in ball-and-stick
representation, and residue 82 is highlighted in yellow. The substrate mutation site (P2) is circled, and regions exhibiting large structural changes
are indicated with arrows. Similarly, panels b and c show the superposition of CA-p2 and p1-p6, respectively, in complex with the WT and V82A
protease variants. Note that there are virtually no conformational changes seen between the WT and V82A complexes in these two complexes.
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their crystallographic statistics, the latter two were chosen for
double difference distance analysis. Only minor changes were
previously observed between these WT and V82A variant
structures (Fig. 2b and c and Fig. 3b and c) (39). The previous
study, which also analyzed WT and V82A variant protease
complexes with two protease inhibitors (saquinavir and ritona-
vir) approved by the Food and Drug Administration, found
that Val82 is more crucial for inhibitor binding than for sub-
strate recognition. However, the large structural deviations we
find in the present study between the WTNC-p1WT and
AP2VNC-p1V82A complexes, along with the coevolution of
AP2V, implicate Val82 as important for the recognition of the
NC-p1 cleavage site.
Hydrogen bonds. All of the substrate complexes of HIV-1
protease show an extensive network of 12 to 18 hydrogen
bonds between the proteases and their respective substrates.
This network also exists in the two NC-p1 substrate-protease
structures (Table 2). Three hydrogen bonds seen in the
AP2VNC-p1V82A structure but not in the
WTNC-p1WT complex
were compensated by two new hydrogen bonds in the latter.
However, the lengths of the hydrogen bonds conserved be-
tween the two complexes differ by 0.2 to 0.8 A˚, with the hy-
drogen bonds in the WTNC-p1WT complex almost always being
longer. The lengths of the conserved hydrogen bonds in the
AP2VNC-p1V82A complex agree well with the average hydrogen
bonding distances for corresponding interactions in the other
substrate-protease complexes (40) (39) (Table 2). Only two
hydrogen bonds in the AP2VNC-p1V82A complex are longer by
0.1 A˚, and six others are shorter by 0.2 A˚ than the average
distance. In the WTNC-p1WT complex, on the other hand, the
hydrogen bond lengths are generally longer by 0.2 to 0.8 A˚
from the average hydrogen bond lengths found in the other
nine protease-substrate structures. Rearrangement of the 
and  angels near the scissile bond in the AP2VNC-p1V82A
complex (Fig. 1) may be attributed to improved hydrogen
bonding in that structure relative to the WTNC-p1WT complex.
In general, the hydrogen bonds between the substrates and
HIV-1 protease involve the peptide backbones (40, 51). This is
also the case in the NC-p1 complexes, where only one substrate
side chain is involved in hydrogen bonds. AsnP1 ND2 makes a
weak hydrogen bond (3.5 A˚) with Gly27 O in the AP2VNC-
p1V82A complex. This is the only substrate complex structure
where a hydrogen bond is observed between the protease and
the side chain of P1. This hydrogen bond, however, is absent in
the WTNC-p1WT structure. Although the side chains of ArgP4,
GlnP3, and LysP4 could possibly be making hydrogen bonds,
they are disordered in both complexes and so cannot be ob-
served. Hence, apart from the lone and weak AsnP1 ND2-
Gly27 O hydrogen bond, there appears to be no stable side
chain hydrogen bond in either complex.
In addition to direct substrate-protease hydrogen bonds, wa-
ter-mediated hydrogen bonds were also examined, as they can
be relevant in rational drug design (22). Out of the five water
sites conserved among HIV-1 protease complexes (23, 25, 40),
only four are observed in the WTNC-p1WT complex (Fig. 4).
However, all five of the water molecules are found in the
AP2VNC-p1V82A complex. The water molecule that is absent in
the WTNC-p1WT complex (Fig. 4, W3) directly mediates sub-
strate backbone (GlnP3 O) with the protease (Gly27 O, Asp29
OD1, and Arg8 NE). Absence of this water bridge, in the
WTNC-p1WT complex may be a direct consequence of the poor
substrate-protease hydrogen bonding.
In addition to the five conserved water molecules, three
other water molecules stabilize the AP2VNC-p1V82A complex.
The side chain of AsnP1 forms a hydrogen bond with W2 (Fig.
4 and Table 3), which itself forms a hydrogen bond with the
conserved W3. W7 mediates interactions between the back-
bone atoms of Gly48 (N) and LysP4 (O) in the AP2VNC-
p1V82A complex. The third water site, W8, bridges the side
chain oxygens of Asp30 with IleP5N. Thus, these three addi-
tional water molecules appear to further stabilize the AP2VNC-
p1V82A complex, whereas the absence of the W3 water site may
be indicative of the higher level of disorder in the WTNC-p1WT
complex.
van der Waals interactions. Both V82A and AP2V muta-
tions involve changes in the size of their hydrophobic side
chains. A detailed examination of the substrate residues P2 to
P2 (GlnP3 is disordered in both complexes and GlyP3 has no
side chain) reveals several rearrangements in packing between
the two complexes. At residue 82, the site of the protease
mutation, packing between PheP1 and residue 82 is lost with
the V82A mutation (Fig. 5a and Table 4). For each substrate
residue, the closest van der Waals contact made by each atom
in that residue with the protease atoms was measured, and
an average contact distance was calculated for the residue.
PheP1, which makes four additional van der Waals contacts to
Gly27, Leu23, Pro81, and Val82 in the WTNC-p1WT complex
is an average of 0.3A˚ closer relative to its contact distance in
the AP2VNC-p1V82A complex. The remaining substrate side
chains within P2 to P2, AsnP1, ValP2, and LeuP2, are signif-
icantly closer to the protease in the AP2VNC-p1V82A complex
by 0.5, 0.4, and 0.4 A˚, respectively (Fig. 5b and c and Table 4),
TABLE 2. Substrate-protease hydrogen bonds formed
















AlaP4 O Gly48 N 3.2 3  3
AlaP4 N Asp30 OD2 2.9 
AlaP3 N Asp29 OD2 3.5 3.3  2.9
AlaP3 O Asp29 N 3.6 2.8  3
Ala/ValP2 N Gly48 O 3.2 2.8  2.9
AsnP1 N Gly27 O 3.2 2.8  2.8
AsnP1 ND2 Gly27 O 3.5 
AsnP1 O Asn25 ND2 3.2 2.5  2.7
LeuP2 N Gly27 O 3.2 2.9  3
LeuP2 O Asp29 N 3.1 2.9  3.2
LeuP2 O Asp29 OD2 3.6 
GlyP3 N Gly48 O 3.1 2.8  2.8
GlyP3 O Gly48 N 3.1 2.8  3
GlyP3 O Asp30 OD2 3.3 
AlaP4 N Asp29 OD2 3.6 3  2.9
AlaP4 N Asp30 OD2 3.5 
AlaP4 O Asp30 OD2 2.4 
AlaP5 N Asp30 OD2 3.3
AlaP6 N Met46 O 2.5
AlaP6 O Met46 N 2.8
a , hydrogen bond is longer in the WTNC-p1WT complex than in the AP2VNC-
p1V82A complex; , hydrogen bond is shorter in the WTNC-p1WT complex than
in the AP2VNC-p1V82A complex. Note that if no distance is listed for a particular
interaction, it is because that distance is well beyond hydrogen bonding distance.
b Average length of corresponding hydrogen bonds found in six substrate-
protease WT complexes (40) and three substrate-protease V82A complexes (39).
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and make 14, 7, and 10 additional van der Waals contacts,
respectively. These additional contacts occur because of a
change in the conformation of AsnP1 (Fig. 1) that enables it to
fit within the pocket formed by Gly27, Pro81, and Asn25 (Fig.
5c). LeuP2 also changes conformation (Fig. 1) and forms
closer van der Waals contacts with Gly27, Ala28, and Asp30
(Fig. 5c). The two added methyl groups in ValP2 allow it to
make new contacts with Val32 CG2 and Ile50 CD. (However,
in the WTNC-p1WT complex, the side chain of Ile50 is disor-
dered in the electron density map.) However, no change is seen
in the conformation of residues Val32, Ile47, and Ile84, which
line the corresponding P2 pocket (Fig. 3a). Thus, except for the
PheP1 Val82 interaction, the overall van der Waals packing in
the AP2VNC-p1V82A complex is better than in the
WTNC-p1WT
complex. The loss of contact from the V82A mutation is com-
pensated by the gain of contacts throughout the AP2VNC-p1V82A
complex due to the AP2V substitution, implicating a subtle ba-
lance of interdependency between the different residues within
the substrate. These results support the previous observation
that the P2 substrate site for HIV-1 protease is preferentially a
-branched amino acid (14) and, in particular, a valine (7).
DISCUSSION
The NC-p1 cleavage site is the rate-determining step in the
processing of the Gag polyprotein (7, 37, 54). The amino acid
sequence of this site, with an Asn at P1 and an Ala at P2, is also
the least homologous compared with the other HIV-1 protease
substrates sites, which have hydrophobic residues at P1 and
branched residues at P2. If either P1 or P2 is replaced with
Phe, Leu, Met, and Tyr or with Val, respectively, the site is
cleaved more efficiently (36). Peptide library screens find that
the P2 site within NC-p1 is preferentially a Val (7). However,
these substitutions are not seen in WT virus, implying that a
more efficient and presumably premature cleavage of this site
may be detrimental to viral maturation (19, 26, 36).
The NC-p1 cleavage site has been seen to coevolve in re-
sponse to the V82A drug-resistant mutation in HIV-1 pro-
tease, with the Ala residue at P2 mutating to a Val (1, 10, 20,
55). Previous studies on the kinetics of substrate cleavage have
shown that this mutation results in the substrate’s being
FIG. 4. Variations in the substrate-protease hydrogen bonds be-
tween the WTNC-p1WT and
AP2VNC-p1V82A complexes. In the super-
imposed active site regions of the WTNC-p1WT (gray and cyan) and the
AP2VNC-p1V82A (magenta and purple) complexes, only those side chains
that form protease-substrate hydrogen bonds are explicitly shown (Asn
25, 25; Asp29, 29; Asp30, 30; and AsnP1). Water molecules are
shown with van der Waals surfaces. The AP2VNC-p1V82A complex forms
additional hydrogen bonds compared with the WTNC-p1WT complex.
These are highlighted with dotted yellow lines (Tables 2 and 3).
TABLE 3. Water-bridging network involving substrates and protease
Water site
WTNC-p1WT AP2VNC-p1V82A
Substrate atom(s) Water Protein atom(s) Substrate atom(s) Water Protein atom(s)
W1 Ala P2 O Wat25 Ile50 N ValP2 O Wat33 Ile50 N
Phe P1 O Ile50 N PheP1 O Ile50 N
W2 Disordered AsnP1 ND2 Wat93 Arg8 NE
Wat27




W4 Wat6 Thr26 O Wat4 Thr26 O
Asp29 OD1 Asp29 OD1
Arg87 NE Arg87 NE
Wat27
W5 LeuP2 O Wat9 Gly27 O LeuP2 O Wat55 Gly27 O
Asp29 OD1 Asp29 OD1
Wat1 Arg8 NE
Wat9
W6 Wat1 Thr26 O Wat9 Thr26 O
Arg87 NE Asp29 OD1
Wat9 Arg87 NE
Wat55
W7 LysP4 Oa Wat112 Gly48 N
W8 IleP5 Na Wat50 Asp30 OD1 and OD2
a These residues are currently modeled as alanines due to lack of electron density.
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cleaved 2.1 times more efficiently (ratios of kcat/Km [mutant
substrate/WT substrate]) for the V82A protease variant and
2.6 times more efficiently for WT HIV-1 protease (12). How-
ever, despite the enzymatic advantage, the AP2V mutation is
not observed in sequences of the WT virus. In this study we
have determined the crystal structures of two NC-p1 substrate
complexes, the WTNC-p1WT complex and the
AP2VNC-p1V82A
complex, in order to understand the structural basis for this
coevolution. Residue 82 is not in direct van der Waals contact
with the P2 site of the substrate, so the coevolution is not as
simple as a decrease in the size of one residue corresponding
to an increase in the size of a neighboring residue. However,
unlike what we have observed in other substrate complexes
(CA-p2, MA-CA, and p1-p6), where the substrates make no or
minimal contact with Val82 (39), in the WTNC-p1WT complex
Val82 does make contact with both AsnP1 and PheP1.
Thus, in comparison with the other WT substrate com-
plexes, residue 82 appears to be more important for recog-
FIG. 5. Variations in the substrate-protease van der Waals interactions between the WTNC-p1WT and
AP2VNC-p1V82A complexes. van der Waals
surfaces of protease residue 82, viewed down the dimer twofold axis, and neighboring atoms of the corresponding NC-p1 substrate: (a) WTNC-p1WT
complex (note that Val82 contacts PheP1) and (b) AP2VNC-p1V82A complex (note that no contact is made between Ala82 and the substrate). Substrates
and proteases are distinguished in gray and black, respectively. A C trace of the overlying flaps is also shown. (c) Active site residues in the WTNC-p1WT.
The protease is shown in gray and the substrate in cyan. Protease residues within 4.2A˚ of the substrate are shown in ball-and-stick representation, and
residue 82 is highlighted in yellow. van der Waals contacts that are lost compared with the AP2VNC-p1V82A complex are highlighted with dotted surfaces
and the P2 site is circled. (d) Active site residues in the AP2VNC-p1V82A. The protease is shown in gray, and the substrate is shown in magenta; protease
residues within 4.2A˚ of the substrate are shown in ball-and-stick representation, and residue 82 is highlighted in yellow. van der Waals contacts that are
lost compared with the WTNC-p1WT complex are highlighted with dotted surfaces, and the P2 site is circled.
TABLE 4. Total number of van der Waals contacts among
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nition of the NC-p1 substrate cleavage site, and when the
drug-resistant V82A mutation occurs, the interactions at P1
and P1 are perturbed.
The question remains of why the loss of contact at P1 and
P1 would affect the residue at P2. Compared with the other
substrate complexes where the P2 residue usually makes van
der Waals contacts with protease residues in its surrounding
pocket, in the WTNC-p1WT complex, the Ala at P2 is unable to
do so. In addition, the hydrogen bonds in the WTNC-p1WT
complex (Table 2) between the substrate and the protease are
longer than those observed in other substrate complexes. The
lack of interactions at the P2 site and the lengthening of the
hydrogen bonds possibly indicate that NC-p1 binds in the ac-
tive site of HIV-1 protease less optimally than in the other
substrate cleavage sites.
In the AP2VNC-p1V82A complex, the PheP1 and, to a lesser
extent, the AsnP1 lose contact with residue 82. This loss of
contact at residue 82 would probably cause the NC-p1 sub-
strate to fit even more poorly within the active site of HIV-1
protease. However, the Val substitution at P2 fills the protease
pocket, allowing van der Waals interactions to occur with the
surrounding protease residues, thereby apparently stabilizing
the conformation of the substrate within the active site. Addi-
tional evidence of stabilization is demonstrated in the hydro-
gen bonding pattern in the AP2VNC-p1V82A complex, which is
more comparable, in terms of both the greater numbers of
hydrogen bonds and shorter hydrogen bonding distances, to
those seen in other substrate complexes (Table 2) than it is to
the WTNC-p1WT complex. The ValP2, therefore, appears to
compensate for the V82A mutation by restabilizing the NC-p1
substrate site through alternative interactions within the
active site cavity. This suggests that for optimal HIV-1 pro-
tease recognition of the NC-p1 substrate site, a possible inter-
dependency exists between the P1 and P2 positions. This in-
terdependency thereby accounts for the seemingly unusual
coevolution of the NC-p1 substrate site (AP2V) with the V82A
drug-resistant mutation within HIV-1 protease. This coevolu-
tion is necessary as the HIV-1 protease drug resistant muta-
tion, V82A, directly impacts the recognition and cleavage of
the NC-p1 site, a rate-determining step in viral maturation.
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